Notice of Proposed Sale · 144
Bausch Health Companies Inc
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Bausch Health Companies Inc.
- Issuer CIK
- 0000885590
- SEC file number
- 001-14956
- Phone
- 514-744-6792
- Person for whose account securities are to be sold
- Lenar Aimee J.
- Relationships to issuer
- Officer
- Street
- 2150 ST. ELZEAR BLVD. WEST
- Street (continued)
- LAVAL
- City
- QUEBEC
- State / country code
- A8
- Postal code
- H7L 4A8
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 36,827 | 258,893.81 | 373,990,561 | 08/19/2026 | NYSE | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/15/2025 | Restricted Stock Vesting | Issuer | 3,428 | N | 07/15/2025 | Compensation |
| Common | 02/26/2026 | Restricted Stock Vesting | Issuer | 18,525 | N | 02/26/2026 | Compensation |
| Common | 07/15/2026 | Restricted Stock Vesting | Issuer | 12,362 | N | 07/15/2026 | Compensation |
| Common | 07/17/2026 | Restricted Stock Vesting | Issuer | 2,512 | N | 07/17/2026 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/19/2026
- Signed
- /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Aimee Lenar
- Plan adoption dates
- 05/21/2026
Company context
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.